ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare…
Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare…
FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage…
MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of…
Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes…
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage…
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic…
NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO,…
WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system…
Dosing of the first subject with BB-301 is expected in the second half of 2023,…
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up…
– Sutro will receive $140 million upfront and is eligible to receive up to an…
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00…
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients…
In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients…